RGT — Argent BioPharma Share News
0.000.00%
Last trade - 00:00- AU$3.56m
- AU$3.48m
- AU$0.16m
Brief: Argent Biopharma Files Provisional US Patent On Immune Modulation And Longevity
Australia's Argent BioPharma rises to over 1-month high on new licence agreement
Brief: Argent Biopharma Signs NLC Licence To Expand Antiviral Portfolio
Brief: Argent Biopharma Says FDA-CVM Established Inad File For Cannepil Veterinary Program
Australia's Argent Biopharma surges on expanding CannEpil license to veterinary care
Australia's Argent BioPharma rises on $5.5 million global licensing deal
Brief: Argent Biopharma Enters Global Licensing Transaction
Brief: Argent Biopharma Enters Long Term Aquiol Licensing And Supply Agreement
Brief: Argent Biopharma Secures A$11M Financing Facility To Complete Strategic Acquisition
Brief: Argent Is Growing Through M&A Projected Merged Company Value Of $100M In Ac8 Asset Acquisition
Australia's Argent BioPharma set for best day in a year on AusCann deal
Brief: Argent Biopharma To Acquire Core Operating Assets And IP Portfolio Of Auscann Group
Brief: Argent Biopharma And Auscann Enters Strategic Heads Of Agreement
Brief: Argent Biopharma Enters Collaboration Agreement For Argent EU GMP Facility In Malta
Brief: Argent Biopharma Says Cannepil Receives Approval For Prescription In Germany
Brief: Argent BioPharma Reports Agreement For Malta Manufacturing Facility
Brief: Argent Biopharma Announces Strategic Partnership With ECCPharm
Australia's Argent BioPharma rises on partnership with ECCPharm
Brief: Argent BioPharma Posts HY Net Loss Attributable A$12.2 Million